XML 16 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Net Income (Loss) $ (14,438) $ (12,300)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 3 4
Non-cash operating lease expense 114 102
Recurring fair value measurements of liabilities (54) 145
Issuance of common stock to vendors 135 0
Loss on disposal of property and equipment 4 0
Stock-based compensation and related charges 652 624
Other 0 (108)
Changes in operating assets and liabilities:    
Prepaid and other current assets and other noncurrent assets 750 705
Accounts payable and accrued liabilities 818 (492)
Accrued compensation and benefits (56) 292
Operating lease liabilities (121) (105)
Net cash used in operating activities (12,193) (11,133)
Cash flows from investing activities:    
Purchases of property and equipment 0 (4)
Net cash used in investing activities 0 (4)
Cash flows from financing activities:    
Payments on insurance financing debt (426) (391)
Proceeds from issuance of common stock and warrants 8,435 9,419
Proceeds from the exercise of warrants 2,506 2,758
Payment of warrant inducement issuance costs (343) 0
Payment of equity issuance costs (576) (617)
Proceeds from issuance of common stock under Employee Stock Purchase Plan 11 17
Shares withheld for payment of employee withholding tax liability (25) 0
Net cash provided by financing activities 9,582 11,186
Net (decrease) increase in cash, cash equivalents and restricted cash (2,611) 49
Cash, cash equivalents and restricted cash, beginning of year 12,458 12,409
Cash, cash equivalents and restricted cash, end of period 9,847 12,458
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:    
Cash and cash equivalents 9,821 12,432
Restricted cash 26 26
Total cash, cash equivalents and restricted cash 9,847 12,458
Supplemental disclosures of cash flow information:    
Interest paid 14 14
Supplemental disclosures of non-cash investing and financing activities:    
Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities 176 0
Non cash impact of exercise price reset on outstanding warrants related to down round provisions 0 16
Fair value of warrants issued to solicitation agent 94 0
Fair value of warrants issued to placement agents 249 384
Fair value of warrants issued to representatives of underwriter 278 0
Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities 37 6
Insurance financing debt included in prepaid and other current assets and other noncurrent assets 347 461
Incremental fair value of modified warrants (Note 5) $ 2,237 $ 0